Semaglutide Reduced Risks of Major Kidney Outcomes Irrespective of CKD Severity in the FLOW Trial

Le résumé fourni par la source

Background Semaglutide reduced risks of major kidney outcomes, cardiovascular (CV) events, and death from any cause in participants with type 2 diabetes (T2D) and chronic kidney disease (CKD) in the FLOW trial. The aim of this analysis was to assess kidney outcomes by baseline CKD severity. Methods Participants had T2D with eGFR 50–75 mL/min/1.73m2 and urine albumin–creatinine ratio (UACR)>300–<5000 mg/g, or eGFR 25-<50 mL/min/1.73m2 and UACR>100-<5000 mg/g. They were randomized to subcutaneous semaglutide 1 mg once weekly or placebo. The FLOW primary outcome was a composite of kidney failure (initiation of chronic kidney replacement therapy, eGFR<15 ml/min/1.73m2),≥50% eGFR decline, or death due to kidney or CV causes. Participants were categorized by baseline eGFR and UACR. Results Among 3533 participants, 30% (n=1069) were women. At baseline, their mean age was 67 years, mean eGFR was 47 mL/min/1.73 m2 , and median UACR was 568 mg/g. The hazard ratio for the primary outcome was 0.76 (95% CI 0.66–0.88) for semaglutide versus placebo over a median of 3.4 years. Consistent results were observed across eGFR and UACR categories. Conclusions Semaglutide safely reduced risks of major kidney outcomes irrespective of CKD severity defined by baseline eGFR or UACR in participants with T2D and CKD in the FLOW trial. Publication History Article published online: 04 May 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.